1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Techne Corp. Reports Operating Results (10-K)

August 27, 2010 | About:

Techne Corp. (NASDAQ:TECH) filed Annual Report for the period ended 2010-06-30.

Techne Corp. has a market cap of $2.17 billion; its shares were traded at around $58.25 with a P/E ratio of 19.8 and P/S ratio of 8.1. The dividend yield of Techne Corp. stocks is 1.7%. Techne Corp. had an annual average earning growth of 14.9% over the past 10 years. GuruFocus rated Techne Corp. the business predictability rank of 5-star.TECH is in the portfolios of Bill Frels of Mairs & Power Inc. , Ron Baron of Baron Funds, Jim Simons of Renaissance Technologies LLC, Columbia Wanger of Columbia Wanger Asset Management, Chuck Royce of Royce& Associates, Bruce Kovner of Caxton Associates, Jeremy Grantham of GMO LLC.

Highlight of Business Operations:

The Company manufactures and sells products for the biotechnology research

and clinical diagnostics market (cytokines, assays and related products) and

the clinical diagnostics market (hematology controls and calibrators). In

fiscal 2010, 2009 and 2008, net sales from the Company's biotechnology

segment were 66%, 66% and 64%, respectively, of consolidated net sales. Net

sales from the Company's R&D Europe segment were 27%, 27% and 30%,

respectively, of consolidated net sales for same periods. The Company's

hematology segment net sales were 7%, 7% and 6% of consolidated net sales for

fiscal 2010, 2009 and 2008, respectively. Financial information relating to

the Company's operating segments is incorporated herein by reference to Note

L to the Consolidated Financial Statements included in Item 8 of this Annual

Report on Form 10-K.

Year Ended June 30,

2010 2009 2008

- - -

Research expense (in thousands):

Biotechnology expenses $ 24,331 $ 22,792 $ 21,632

Hematology expenses 790 772 762

- - -

$ 25,121 $ 23,564 $ 22,394

= = =

Percent of net sales 9.3% 8.9% 8.7%

In fiscal 2004, the Company purchased a 10% equity interest in Hemerus

Medical, LLC (Hemerus) for $3.0 million. In fiscal years 2006 through 2008,

the Company invested an additional $1.8 million in Hemerus, increasing its

ownership percentage to 19%. In fiscal 2010, as a result of Hemerus issuing

additional ownership units, the Company's ownership percentage decreased to

13.8% as of June 30, 2010. Hemerus was formed in March 2001 and has acquired

and is developing technology for the separation of leukocytes from red blood

cells and to extend the shelf life of the isolated blood products. Hemerus

owns two patents, has several patent applications pending and has received

FDA clearance to market its products in the U.S. In parallel with this

investment, R&D Systems entered into a Joint Research Agreement with Hemerus.

The research involves joint projects to explore the use of Hemerus' filter

technology to applications within R&D Systems' Hematology and Biotechnology

Divisions. Such applications, if any, may have commercial potential in other

laboratory environments. The Company accounts for its investment in Hemerus

under the equity method of accounting as Hemerus is a limited liability

company. The Company's net investment in Hemerus was $1.2 million and $2.2

million at June 30, 2010 and 2009, respectively.

In fiscal 2007, the Company invested $7.2 million for an 18% equity interest

in Nephromics LLC (Nephromics). Nephromics has licensed technology related

to the diagnosis of preeclampsia and has sublicensed the technology to

several major diagnostic companies for the development of diagnostic assays.

In fiscal 2008, Nephromics issued additional membership units which reduced

the Company's ownership percentage to 16.8%. In fiscal 2009 and fiscal 2010,

the Company received distributions of $1.3 million and $50,000, respectively

from Nephromics. The Company accounts for its investment in Nephromics under

the equity method of accounting as Nephromics is a limited liability company.

Its net investment in Nephromics was $4.0 million and $4.5 million at

June 30, 2010 and 2009, respectively.

Read the The complete Report

About the author:

Charlie Tian, Ph.D. - Founder of GuruFocus. You can now order his book Invest Like a Guru on Amazon.

Rating: 4.0/5 (2 votes)


Please leave your comment:

Performances of the stocks mentioned by 10qk

User Generated Screeners

daftheadersg hk best
henrikLynch inspiret Oct 17
lajor10Low EV/EBITDA
canidPE >50th percentile of INDUSTR
brucexoct 17 user defined screen
AngryQuality Growth cheap
EnjoylifeDad 1
punjanoot2007a academy+joe
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat